To determine the serum concentrationsof human chononic gonadotropin (hCG), its free f3-subunit (hCG/3), and the free a-subunit (free a) common to all human glycoprotein hormones under physiologicaland pathologicalconditions, we developed monoclonal antibody-based immunoenzymometric assays. Free a-subunit was detected in the sera of all healthy individualsof both sexes; hCG was measurable in sera of 54% of the men, and 46% were positivefor free hCGj3; in nonpregnant women, 69.5% were positive for hCG, 68.4% for the free $-subunit. Pathological conditions, i.e., hCG-producing tumors, were studied in vitroand in vivo. In vitro, the concentrationsof hCG, free hCG/3, and free a in tissue-culture supemates of a chonocarcinoma cell-line ("JAR") showed a parallel pattern during timecourse analysis. In vivo, in long-term follow-up studies of 13 patients with testicular cancer, serum concentrationsof the three analytes paralleled each other, whether the disease was in remission or not. Because of a selective increase of free hCG(3 and free a in 27% of seminomatous tumor patients and in 13% of the nonseminomatous patients, the percentage of tumor-marker-positive sera was increased from 15% to 42% and 57% to 70%, respectively, by the additional measurement of free hCG(3 and free a. Thus hCG, free hCG(3, and free a are physiologically present in a high percentage of the sera from healthy men, and the determination of free hCG/3 and free a, although not of prognostic value, improves the diagnostic possibilities in patients with testicular cancer. (7) . The (3-subunits, however, are hormone-specific and are encoded by several genes (8). Recent studies detected the common free a-subunit in the sera of healthy individuals. However, the physiological serum values reported by various authors ranged between 50 and 3000 ng/L. These discrepancies might be attributable to the use of insensitive and or nonspecific assay systems (9-11). The free (3-subunit has not been detected regularly in the sera of a healthy population. The importance of hCG as a tumor marker has long been recognized (1,2,10). In contrast, the diagnostic and prognostic value of free hCG(3, and especially of free a subunit, for trophoblastic and nontrophoblastic malignancies is not fully established (12, 13). There is a lack oflongitudinal studies elucidating the secretion pattern ofthesesubunitsunder successful or unsuccessful polychemotherapy, and no studies are available involving a larger group of patients in whom all three markers are analyzed simultaneously.
certain malignancies, e.g., molar pregnancy, choriocarcinoma, and testicular cancer (1, 2). The presence of hCG in the sera of healthy, nonpregnant individuals suggests an additional, extratrophoblastic site of production (3, 4) . A parallel secretion pattern with human luteinizing hormone (hLH; lutropin), the demonstration of hCG in the pituitary gland, and a stimulatory effect of exogenous luteinizing hormone-releasing hormone (LHRH; luliberin), indicate that hCG might be synthesized in the pituitary (3) (4) (5) (6) . The physiological role of extratrophoblastic hCG is still unknown. Like any member of the human glycoprotein hormone (hGPH) family, hCG is composed of two subunits, designated a and (3. The a-subunit is identical within the four hGPHs and is encoded by a single gene (7) . The (3-subunits, however, are hormone-specific and are encoded by several genes (8). Recent studies detected the common free a-subunit in the sera of healthy individuals. However, the physiological serum values reported by various authors ranged between 50 and 3000 ng/L. These discrepancies might be attributable to the use of insensitive and or nonspecific assay systems (9) (10) (11) . The free (3-subunit has not been detected regularly in the sera of a healthy population. The importance of hCG as a tumor marker has long been recognized (1,2,10). In contrast, the diagnostic and prognostic value of free hCG(3, and especially of free a subunit, for trophoblastic and nontrophoblastic malignancies is not fully established (12, 13). There is a lack oflongitudinal studies elucidating the secretion pattern ofthesesubunitsunder successful or unsuccessful polychemotherapy, and no studies are available involving a larger group of patients in whom all three markers are analyzed simultaneously.
We previously produced a series of monoclona.l antibodies (MCAs) against hCG, free hCG(3, and free a to explore the antigenic epitopes of these molecules and hormone-receptor interaction sites, and to establish immunoassays with predictable specificities (14) (15) (16) (17) (18) . We have now used these MCAs to establish two-site assays for hCG, free hCGf3, and free a of better sensitivity and specificity than in previously published procedures. We have also determined the serum concentrations of hCG and its free subunits under physiological and pathological conditions, such as testicular cancer.
Materials and Methods
Serum samples. To define physiologically normal concentrations of hCG, free hCG/3, and free a, we obtained serum samples from apparently healthy men (n = 15) and women in their luteal and follicular phases of the 
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PhysiologicalSerum Values in NonpregnantSubjects
Sera from 15 apparently healthy men and 75 women were simultaneously analyzed for their serum content of hCG, free hCG$, and free a ( Table 3 ). The positive correlation between the concentrations of hCG and free hCGI3 in serum was statistically significant (P <0.001); the free a-subunit did not correlate with hCG or free hCG (P >0.05) but did correlate with hLH and hFSH (P <0.001 and <0.01, respectively). The physiological range of hCG, free hCGI3, and free a in the sera of the men was defined as the mean + 3 SD (-99.7% confidence interval): 240 ng/L for hCG, 190 ng/L for free a, and 50 g/L for free hCGj3.
Secretionof Free a after LHRH Administration
Before the administration of LHRH, the weight ratio in serum of the free a-subunit to hLH plus hFSH was -0.08; this increased to >0.2 by 30 mm after LHRH stimulation (Figure 2) . The concentration of free a-subunit increased at least fivefold after LHRH administration.
hCG, Free hCG, and Free a Concentrations under PathologicalConditions
In vitro: The tissue-culture supernates of the choriocarcinoma cell line JAR were analyzed for changes in hCG, free hCG, and free a over time (0.5-96 h) ( Figure  3 ). All three markers were detectable after 0.5 h. hCG was the analyte in highest concentration, followed by free a, and free hCGJ3. The weight ratios of hCG, free a, Because of the selective increase of free hCG/3 and free a in 13% of the nonseminomatous patients and, more notably, in 27% of the seminomatous patients, the percentage of tumor-marker-positive sera was significantly greater when measurements of free a and free hCG/3 were included than when only hCG was measured (Figure 5 ).
DiscussIon
The utility of determinations of hCG, free hCG/3, and free a is still a matter of debate (20) . The application of 10' (21) , given the extensive homology of the /3-subunits of these two hormones (22) . Furthermore, hGPH homogeneity hinders specific quantification of the free a-subunit (23). By utilizing MCAs and adequate assay designs, we could develop highly sensitive and specific assays for hCG, free hCGf3, and free a (Figure 1) . To reliably determine free hCG/3 and free a, even in the presence of a 100-to 1000-fold excess of the holo-hormone (Figure  4) , we chose capture MCAs in our IEMA5 that excluded even a theoretical interference from the free subunits or holo-hormones in the respective assays because we used MCAs specific to free a-, /3-and conformational-determinants of holo-hCG as coating antibodies for the respective assays (Table 2) .
Discrepancies in the physiological serum concentrations, as exemplified in Figure 6 for the free a-subunit in serum, could be due to nonspecific assay systems (9, 11,
24-27).
Reported physiological mean values differ at least 10-to 20-fold. Ozturk et al. (26) , using a specific MCA-based two-site assay system with a sensitivity for free a of 200 ngfL, did not detect free a in the sera of healthy men ( Figure 6 ). This indicates that the serum concentration of the free a-subunit is below the detection limit of that assay, i.e., <200 ngfL. A recent publication (9) and our data indicate that, in men, the physiological concentration of free a subunit in serum is -70 ng/L; in women, mean values are higher (Table 3) .
There is a paucity of data on the physiological serum concentrations of free hCG /3-subunit. Again, Ozturk et al. (26), using an assay with a sensitivity for hCG/3 of 200 ngfL, did not detect physiological free hCG/3. We found here that the physiological concentration of free hCG/3 in men is in the 10-30 ng/L range. However, because these concentrations are close to the lower detection limit of the hCG/3 IEMA and because 54% of the samples from men were below the detection limit of the hCGI3 IEMA, these results must be confirmed by using even more-sensitive assay systems.
Physiological serum concentrations of holo-hCG are better documented. Using a very sensitive two-site immunoradiometric assay, Griffin and Odell (3,4) demonstrated detectable holo-hCG in all eugonadal adults when multiple samples were quantified. When single serum samples were analyzed, 73% of the men were positive for hCG, compared with 54% in our series of healthy individuals.
The physiological serum values were -50 ngfL. The concentrations of hCG increase in older men and in postmenopausal women (5).
The source of physiological hCG, free hCG3, and free a is most likely the pituitary gland. hCG was demonstrated in pituitary extracts and in cell-culture supernates of human pituitary cells (6, 28) . A high positive correlation of the free a-subunit to gonadotropin concentrations, a stimulatory effect of LHRH agonists, and suppression of free a-secretion of LHRH antagonist provide further evidence for this theory, which is substantiated by parallel secretion of free a with hLH and hFSH (5,11) . The discordant rise of free a after LHRH administration and a delayed response to an LHRH antagonist compared with the response of hLH, suggest at least partially independent secretion of free a ( Figure  3 ) (11) . The positive correlation of hCG and hCGI3 in serum indicates a co-secretion of hCG and free hCG/3.
Metabolic degradation of holo-hormones as sources of serum free hCG/3 and free a can be excluded, because intravenous infusion of purified hLH into humans led to a significant increase in serum hLH, whereas no change in the serum concentrations of free a was observed (29) . Moreover, the half-life of free hCGf3 is only one-tenth that of hCG, and the half-life of free a is 40-and 240-fold shorter than hLH and hFSH, respectively (31).
Apart from the presence of hCG, free hCGf3, and free a in the sera of healthy individuals, these molecules play an important role as diagnostic tumor markers for various malignancies (1, 12, 13), the most prominent of which are trophoblastic neoplasms (1, 13). Our studies on the secretion pattern of hCG, free hCGI3, and free a by malignant transformed trophoblastic cells in vitro and in vivo revealed parallel concentration curves under both circumstances, with a statistically significant correlation (P <0.001) between the three markers in cell-culture supernates and sera of choriocarcinoma patients. In vitro and in vivo differences in the free subunit ratios are probablydue to metabolicdifferences, given that the half-life of the free a-subunit in serum is much shorter than that of the free hCG /3-subunit. This phenomenon changes the in vitro ratio of free hCGf3/free a from 1:5 to values in the range of 1:lto 10:1 in vivo (28) . The high correlation between hCG, free hCG/3, and free a in choriocarcinoma patients contrasts with the discordant increase of free subunits during pregnancy (30) . Long-term follow-up studies of our patients with choriocarcinoma revealed parallel concentration curves for hCG, free hCG/3, and free a. In all cases, hCG was the marker with the highest concentration (10, 13,26) . No dramatic changes in the ratios of the three molecules was observed, whether the tumor was progressing or not. In contrast to some reports (17) , we did not observe changing ratios of the three markers after chemotherapy. The group of patients with chemotherapy-resistant tumors showed a significant (P <0.05) decrease of the ratio, hCG/free a, i.e., an increased free subunit propor- The diagnostic sensitivity, especially forthefreehCG /3-subunit and the holo-hormone, has been extensively studied (13, 32, 33) . Saller et al. (13) reported that measurement of hCG and free hCG/3 simultaneously in a single assay, or with two separate test kits, most reliably detects these malignancies. In our sample of 33 seminomatous and 76 nonseminomatous testicular cancerpatients, a selective increase offreehCGI3 was observed in 12% and 1% ofallsera, respectively. The commerciallyavailable hCG-kits reveal, at best, cross-reactivity for free hCG/3 of 264%, too low to detect selective increases in free hCGf3 at low concentrations (13) . Therefore, separate assays for hCG and free hCGp, or hCG-kits with cross-reactivities for free hCG/3 (on a molar basis) of <700%, are required (13) .
The diagnostic potential of measuring the free a-subunit in testicular cancer patients has not yet been studied extensively. As with free hCG/3, some patients present selective increases of the free a-subunit. Its additional measurement increases the percentage of tumor-marker-positive sera (Table 5 ). However, the free a-subunit displayed the least increase overphysiological values and was the first to return to physiological concentrations after successful chemotherapy ( Figure  4 ). These facts indicate that an increase in free a-subunit in sera of patients with testicular cancer should be interpreted cautiously.
The clinical significance of a selective increase of free hCG/3 and free a needs further investigation, particularly to clarify whether these patients have a poorer prognosis than those presenting with increases of hCG alone, or of all three markers. Selective increase of the nonassembled subunits might indicate a significant dedifferentiation of tumor cells.
In conclusion, we demonstrated the presence of free hCG/3 and free a in the sera of healthy individuals by using highly specific and sensitive MCA-based IEMAs. This enabled us to define physiological ranges for the respective hormones and free subunits in sera. A subsequent study of testicular cancer patients revealed that the diagnostic sensitivity for testicular cancer patients could be significantly increased by analyses for free hCG/3 and free a as well as hCG.
